» Articles » PMID: 35684402

MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2022 Jun 10
PMID 35684402
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic ductal adenocarcinoma and cholangiocarcinoma constitute two aggressive tumor types that originate from the epithelial lining of the excretory ducts of the pancreatobiliary tract. Given their close histomorphological resemblance, a correct diagnosis can be challenging and almost impossible without clinical information. In this study, we investigated whether mass spectrometric peptide features could be employed to distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma. Three tissue microarrays of formalin-fixed and paraffin-embedded material (FFPE) comprising 41 cases of pancreatic ductal adenocarcinoma and 41 cases of cholangiocarcinoma were analyzed by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). The derived peptide features and respective intensities were used to build different supervised classification algorithms: gradient boosting (GB), support vector machine (SVM), and k-nearest neighbors (KNN). On a pixel-by-pixel level, a classification accuracy of up to 95% could be achieved. The tentative identification of discriminative tryptic peptide signatures revealed proteins that are involved in the epigenetic regulation of the genome and tumor microenvironment. Despite their histomorphological similarities, mass spectrometry imaging represents an efficient and reliable approach for the distinction of PDAC from CC, offering a promising complementary or alternative approach to the existing tools used in diagnostics such as immunohistochemistry.

Citing Articles

Spatial Proteomics by Parallel Accumulation-Serial Fragmentation Supported MALDI MS/MS Imaging: A First Glance Into Multiplexed and Spatial Peptide Identification.

Li M, Meyer L, Meier N, Witte J, Maldacker M, Seredynska A Rapid Commun Mass Spectrom. 2025; 39(9):e10006.

PMID: 39910729 PMC: 11799399. DOI: 10.1002/rcm.10006.


Exploring new frontiers in type 1 diabetes through advanced mass-spectrometry-based molecular measurements.

Sarkar S, Zheng X, Clair G, Kwon Y, You Y, Swensen A Trends Mol Med. 2024; 30(12):1137-1151.

PMID: 39152082 PMC: 11631641. DOI: 10.1016/j.molmed.2024.07.009.


Application of AI on cholangiocarcinoma.

Huang J, Bai X, Qiu Y, He X Front Oncol. 2024; 14:1324222.

PMID: 38347839 PMC: 10859478. DOI: 10.3389/fonc.2024.1324222.


Spatial pharmacology using mass spectrometry imaging.

Rajbhandari P, Neelakantan T, Hosny N, Stockwell B Trends Pharmacol Sci. 2023; 45(1):67-80.

PMID: 38103980 PMC: 10842749. DOI: 10.1016/j.tips.2023.11.003.


Advances in Imaging Mass Spectrometry for Biomedical and Clinical Research.

Djambazova K, van Ardenne J, Spraggins J Trends Analyt Chem. 2023; 169.

PMID: 38045023 PMC: 10688507. DOI: 10.1016/j.trac.2023.117344.


References
1.
Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

2.
Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B . Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1:7-18. DOI: 10.1111/liv.14093. View

3.
Fasanella K, Krasinskas A, Schoedel K, Sasatomi E, Slivka A, Whitcomb D . DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma. Pancreatology. 2010; 10(4):429-33. DOI: 10.1159/000318807. View

4.
Le Faouder J, Laouirem S, Alexandrov T, Ben-Harzallah S, Leger T, Albuquerque M . Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry. Proteomics. 2014; 14(7-8):965-72. DOI: 10.1002/pmic.201300463. View

5.
Loch F, Klein O, Beyer K, Klauschen F, Schineis C, Lauscher J . Peptide Signatures for Prognostic Markers of Pancreatic Cancer by MALDI Mass Spectrometry Imaging. Biology (Basel). 2021; 10(10). PMC: 8533220. DOI: 10.3390/biology10101033. View